A detailed history of Steward Partners Investment Advisory, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Steward Partners Investment Advisory, LLC holds 6,720 shares of EXEL stock, worth $239,299. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,720
Previous 3,656 83.81%
Holding current value
$239,299
Previous $82,000 112.2%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$21.96 - $27.6 $67,285 - $84,566
3,064 Added 83.81%
6,720 $174,000
Q2 2024

Aug 08, 2024

BUY
$20.34 - $23.73 $1,525 - $1,779
75 Added 2.09%
3,656 $82,000
Q1 2024

May 15, 2024

BUY
$20.17 - $23.93 $5,768 - $6,843
286 Added 8.68%
3,581 $84,000
Q4 2023

Feb 12, 2024

BUY
$19.25 - $24.13 $63,428 - $79,508
3,295 New
3,295 $79,000
Q4 2022

Feb 15, 2023

BUY
$14.96 - $17.39 $598 - $695
40 New
40 $0

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.5B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Steward Partners Investment Advisory, LLC Portfolio

Follow Steward Partners Investment Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Steward Partners Investment Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Steward Partners Investment Advisory, LLC with notifications on news.